By Fineline Cube 
China‑based SSY Group Limited (HKG: 2005) announced today that it has been pre‑selected as the proposed winner for 12 pharmaceutical products across 14 specifications in the Eleventh Round of the National Volume‑Based Procurement (VBP) program. The successful items include a mix of injectables, inhalation solutions, tablets and electrolyte solutions, underscoring SSY’s broad portfolio and its alignment with the government’s cost‑control strategy.
Proposed Winning Products
| Product | Specification |
|---|---|
| Diprofylline injection | 2 ml : 0.3 g |
| Formoterol fumarate inhalation solution | 2 ml : 20 µg |
| Fluvoxamine maleate tablets | 100 mg / 50 mg |
| Lornoxicam injection | 8 mg |
| Epinephrine hydrochloride injection | 1 ml : 1 mg |
| Bromhexine hydrochloride injection | 2 ml : 4 mg |
| Compound electrolyte injection – I | 500 ml |
| Compound electrolyte injection – II | 500 ml / 1000 ml |
| Nicorandil tablets | 5 mg |
| Salbutamol sulfate injection | 1 ml : 0.5 mg |
| Benidipine hydrochloride tablets | 8 mg |
| Sodium bicarbonate injection | 50 ml : 4.2 g |
Context & Implications
- Strategic Alignment – SSY’s inclusion of both established and niche therapeutics positions it to capture a sizable share of the national procurement market, potentially driving revenue growth and market penetration.
- Competitive Landscape – While Shijiazhuang Pharmaceutical Group had previously secured 14 designated‑brand drugs, key drugs such as phenylephrine and dobutamine mesylate were not part of SSY’s winning list.
- Regulatory Status – The National Joint Procurement Office has not yet issued the final winning bid list; SSY’s status remains provisional pending formal confirmation.
Forward‑Looking Statements
This release contains forward‑looking statements that involve risks and uncertainties. Actual results may differ materially.-Fineline Info & Tech